Edgen Stock·Sep 29 2025, 12:48戻る
戻る
Editas Medicine Designates EDIT-401 as Lead Gene-Editing Candidate for Hyperlipidemia
Edgen Stock·Sep 29 2025, 12:48
[1] Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program (https://finance.yahoo.com/news/editas-medicin ...)[2] Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol - Nasdaq (https://www.nasdaq.com/articles/editas-nomina ...)[3] Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate (https://vertexaisearch.cloud.google.com/groun ...)